Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial

Mukul M Sharma , Robert Ha , Stuart Connolly , Jackie Bosch (1) , Olga Shestakovska , Kelvin Ng , Luciana Ha , Katalin Keltai , Victor Aboyans (2, 3) , Marco Alings , Jong-Won Ha , John Varigos , Andrew Tonkin , Martin O'Donnell , Deepak Bhatt (4) , Keith A.A. Fox (5) , Aldo Maggioni (6) , Scott Berkowitz , Nancy Cook Bruns (7) , Salim Yusuf (8) , John Eikelboom (9) , Robert Hart , Kelvin K.H. Ng , Luciana Catanese , Deepak Ha , Salim Ha

1 Population Health Research Institute
2 Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges]
3 NET - Neuroépidémiologie Tropicale
4 VA Boston Healthcare System
5 Edin. - University of Edinburgh
6 ANMCO Research Center - Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri]
7 Bayer Pharma AG [Berlin]
8 Hamilton General Hospital
9 McMaster University [Hamilton, Ontario]

Strokes were significantly reduced by the combination of rivaroxaban plus aspirin compared with aspirin in the COMPASS Trial. We present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups.

URL: https://www.clinicaltrials.gov Unique Identifier: NCT01776424.

Mots clés: rivaroxaban

Domaines: Santé publique et épidémiologie

Mukul M Sharma, Robert Ha, Stuart Connolly, Jackie Bosch, Olga Shestakovska, et al.. Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial. Circulation, 2019, ⟨10.1161/CIRCULATIONAHA.118.035864⟩. ⟨hal-02044345⟩